drugset / Trial / NCT06792019
Study of CM313(SC) Injection in Subjects With Platelet Transfusion Refractoriness
RandomizedParallel-groupOpen-labelTreatment
Summary
This is a randomized, open-label, phase IB/II clinical study to evaluate the safety and preliminary efficacy of CM313(SC) injection in patients with Platelet Transfusion Refractoriness.
Timeline
- Start
- 2025-03-25
- Primary completion
- 2027-11-16
- Completion
- 2027-11-16
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | LUMROTATUG | Monoclonal antibody | — | Subcutaneous |